Search for: "Sanofi S A" Results 161 - 180 of 933
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
14 Jan 2011, 11:14 am by Tom Lamb
s with no other apparent causes of liver injury or known elevations of liver function tests (LFTs) prior to the acute liver failure. [read post]
22 Nov 2010, 5:42 am by CorporateAcquisitions MergerLawBlogger
Gina Chon and Preeta Das at the WSJ have an article this morning suggesting that Genzyme might be open to a deal with Sanofi if it's given certain back-end protections for its shareholders. [read post]
14 Nov 2008, 2:25 am
It is produced and marketed by Procter & Gamble and Sanofi-Aventis. [read post]
14 Jan 2011, 8:21 am by Ronald V. Miller, Jr.
Avalide, a blood pressure medication, has been recalled by Bristol-Myers Sanofi-Aventis because a manufacturing problem could affect the drug's efficacy. [read post]
28 Mar 2023, 1:15 pm by Eileen McDermott
Sanofi was long-awaited and closely watched by many in the patent community. [read post]
23 Dec 2010, 7:48 am by Lawrence B. Ebert
Sanofis arguments notwithstanding, the parties directly dispute the meaning and effect of the “decision(s) enjoin-ing” language in Section 3.5 of the license agreement. [read post]
11 Jan 2024, 9:31 pm by Patent Docs
Sanofi decision: What’s Next for Biotechnology Claims? [read post]
30 Oct 2014, 8:21 am by Howard Knopf
Here's the Court's official summary - which doesn't necessarily indicate precisely what the real issues will turn out to be:35886Sanofi-Aventis, et al. v. [read post]
28 Sep 2009, 9:05 pm
Class Action Complaint Alleging Securities Fraud Violations Arising from Disclosures Concerning Drug under Development Failed to State Claims under Section 10(b) of the Securities Exchange Act of 1934 or Rule 10b-5 New York Federal Court Holds Plaintiffs filed a putative class action against French pharmaceutical company Sanofi-Aventis and certain individual defendants alleging violations of the Securities Exchange Act of 1934; specifically, the class action complaint alleged that… [read post]
21 Apr 2021, 4:15 am by Daniel Shores
Translate BIO also appears to have one infectious disease candidate in the “IND-enabling” Phase (with Sanofi), and three lung candidates, one liver candidate, and two infectious disease candidates (with Sanofi) in the discovery phase. [read post]
6 Jan 2017, 6:04 pm by Michael Baseluos
Today, post market surveillance has shown Sanofis claims of superior efficacy to be fraudulent. [read post]
6 Jan 2017, 6:04 pm by Michael Baseluos
Today, post market surveillance has shown Sanofis claims of superior efficacy to be fraudulent. [read post]
9 Aug 2018, 5:16 pm by Dennis Crouch
Sanofi, Aventisub LLC, SCT Docket No. 18-127 (Petition filed July 23, 2018) (Cert Petition). [read post]
9 Apr 2012, 4:00 pm by Courtenay Brinckerhoff
., the Federal Circuit upheld the district court’s finding that two of the Orange Book listed patents for Sanofi Aventis’ cancer drug Taxotere are unenforceable for inequitable conduct. [read post]
29 Sep 2010, 2:24 am by By DEALBOOK
Genzyme's chief executive, Henri Termeer, has suggested he is more open Sanofi-Aventis's proposed takeover of the biotechnology company than at any point in the past, telling The Financial Times, he would be prepared step down to facilitate the deal. [read post]
9 Jan 2017, 9:36 am by Lawrence B. Ebert
IPXL announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg. [read post]
29 Jan 2008, 3:13 pm
Congress Wants To Know When Sanofi-Aventis And The FDA Learned About Fraud Involved With Ketek Study 3014 (Posted by Tom Lamb at DrugInjuryWatch.com) Soon after noon on January 29, 2008 Ed Silverman posted on his Pharmalot blog an article, "House Committee Will Subpoena FDA Over Ketek", which reported this breaking news about the Congressional investigation into Ketek, Sanofi-Aventis, and the FDA:At its hearing this morning, the House Energy and Commerce… [read post]